Here, we validated this hypothesis using molecular and pharmacological approaches and, in so doing, obtained a preclinical basis for repurposing FDA-approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for obesity management. This evidence concerns the gene CDK4 and obesity disorder.